joining for all you us today. Thank
is and a call being available. webcast ir.navidea.com, website, our on replay live This will made be
Following joining questions be we will Finance and Navidea's prepared question-and-answer Eves, of the remarks, where will call Erika segment be Vice conducting President will on provide and a submitted Administration, our me responses. read we today.
and and the with of immunotherapeutics, data events well which capital future include of along of course impact will clinical plans the Navidea's COVID-XX be statements These regarding and pandemic we as regulatory the business this readouts matters performance making future as call, events timing developments, to conference of on the resources Navidea's to During molecular strategic and the and operations. our diagnostics relate company. forward-looking develop clinical business
results these of assumptions, could the and expectations whether of statements as beliefs assume as revise certain or and actual on differ are These and future risk update risks involve new management the All obligation most forward-looking the of events the no with safe recent website and section otherwise. statements as read carefully Investors to information, in uncertainties, the described a risks harbor statements of materially. to today. We of based result our well annual filings as within factors should included and the uncertainties or quarterly company's SEC. cause
Smith, office executive like company brief a an to begin as committee his of CEO and a company's of Mike the Erika an includes Finance company's while positions the on company's The Board and to lead from will Leadership Rosol, I'd Directors Executive President Operations. Officer; President Barb I Medical November Directors, Leadership CEO events. basis Vice quarter newly Eves, On XX. a and established Committee the of of Oversight Board Jeffrey of leadership on K. October myself, its Thomas the XXXX, our is identified. of Chief committee provide Independent interim Committee executive established Vice Board transitioned Executive VP Jr. update, John member CEO the Capello, [Jed the and The former the Administration; the resigned consisting next Before on and from Senior X, and the third work with recent Alexandre comment Latkin], and
rheumatoid II on to During In the our clinic. advance September had completed while we discuss rheumatoid meeting working pipeline on Phase we quarter, focused the results also this remain B aggressively therapeutics of the arthritis transition, X, program Type into third our our to of end the Phase III IIb the III that meeting trial We plan protocol that upon analysis RA. advancement the with on FDA, and our discussion. Phase arthritis received meeting NAVX-XX had formal in minutes have and agreed and modifications a with submitted constructive based Phase of into have in
as actively the past of brought call. initiation the are comments Officer. Mikhail the have our in update the trial. for I'll quarter, more preparing In in moment Chief in Dr. RA We program clinical of Regulatory this also a we Michel portion some on
Europe. the as clinical advance with we readily basis. him team Ohio daily on Lymphoseek to closely here. Michel regulatory RA moved a X distribution few. press now program, served has with SmithKline roles is And in a have GSK; Beecham, excited to As Germany have at pharmaceutical AG; industry, can and [Upjohn], so we he working Dr. our Pharmacia now you read name to interact and has the here and Pfizer, years of in the might in has experience Dr. in XX that of manage We're him the BioNTech release, and in over Michel
brings Capello shareholder. of Scott Mr. John of company's also company. board This largest Winkler. the of is the over Farm Scott and XX banking information and has Board And several Jr., And extensive decades years in Board members. as Cabello, investor companies, over saw the Alexander Mr. Thomas companies. with of executive experience Fortune and the technology appointments science experience has X Mr. internationally. mid-cap an quarter both Ms. public Farbanca senior Winkler experience U.S. and for XXX professional life numerous in and start-up, and
cover to like would I update. Now the clinical
on begin interactions update progress our program on the with RA with I'll FDA. the an and So our
our review submitted B Phase a The were it their the data we As protocol for package discussed as moving trial, meeting IIb proposed Type in the well III IIb evaluation July, previously, and trial II continuing in of us agency NAVX-XX, of have to end completed RA. the plan. Phase Phase critical from to Phase as forward we of the analysis and
RA. ability this III tilmanocept study obtain X to repeatability, treatment with patients a and reminder, readout X-arm sample trial. was the and In Phase of of our to imaging for first X, and And the As third Phase a upcoming the both stability the to in active imaging tilmanocept evaluated a look arms arm, reproducibility efficacy. as healthy subjects in mirrored serve we with and we predictor data of early have at sizing III the help to an in
a for powerful possible the tilmanocept results using standard that high to initial patients predictive therapy group defined work tool on of the tilmanocept was single to to be the to active can The results the quantitative define tilmanocept and rheumatologists be efficacy imaging joints with we gold alone to of scan the a exhibiting in time and RA unlikely that the alpha therapies subtype This data of disease likely of nonresponders from our a robust from be otherwise capacity previously, the worsening baseline case. those of complete in baseline arm the value, on could fibroid arm uptake data from joints would a support of the international XX% anti-TNF the this effects effect and trial As submitted subset the their can with set in side meeting. accuracy the point to clinical therapy. own, trial be RA-involved of even for prediction provide strong rule plan In the write short, and in patients. controls the particular reproducible hypothesis. at from in this course, combination these provide is from treatment cost, in presentation imaging patients of class early full alpha at and There will saw particular inflammation, it's scan early therapies alpha scan, for a X rest patients, In we from anti-TNF a rate these for of journal. without use subjects, data can completed of timely low healthy avoiding up assessment. possible an ability the the prediction demonstrated to an continue entire alpha anti-TNF able set analysis predictive an who to anti-TNF predict with on that get represents its And patients to treatment go, discussed an medical of that and out imaging nonresponse level so-called high therapy that with publication demonstrated RA. upcoming of In we X almost the
Phase modifications Following our the [indiscernible] the FDA, site of the the whom RA with and plan, for U.K. we as the Several constructive preparing instrumental comments we protocol to with meeting initiate their II of we us study meeting. III Jonathan rheumatology, meeting to these In submission send this it in NAVX-XX back included preparation and and initial make FDA meeting, opinion design the September us their Phase the interim, in Dr. the as the in results been preliminary analysis our and III sent of itself replies to after Tino key comment. UCSF request as analysis opportunity our and for agency days the alignment, Phase constructed Costin efficient September well in was the briefing of are leaders and well quarter. end and X advisers protocol and package this Bras September agreed-upon Petalas granted X. sent receipt to back in development to Phase meeting program to X prior trial date containing III II have of meeting X minutes the formal on design. sure as Phase these set program comments, Dr. for the both an FDA providing plan, in the Since to finalized the of remain investigators The
we are that As that have were open continue that to well the I've benefit with will as automating Phase are progress have and we operations. want IIb make trial several expect which I quickly. study imaging also the good in mention the quantification the involved be to we design very commercial product. before, well, key and sites to These to mentioned sites significant on up acquainted able to
will nearly III from the joints have completed what limited well data normal database. integral have that RA, from is the This of enable our Phase response. We study knowledge we control norm use parameters, product. us the the inflamed Arm like in This quantitatively. those with to of part our tilmanocept, commercial joints accuracy to RA-inflamed size the essential for IIb study, should start an treatment analysis normative a this joints called is with both like predict discriminate completed the to of current what database use add of to healthy ability do to NAVX-XX, a and in X joint ability an part set the and non-RA positive We to what have to healthy the inflammation as RA-involved from will of Phase improved parameters as should establishing establish to control tilmanocept in database healthy impact looks on not discriminate a the joints play data look
projected and track As but X on all are we've to enrolled of enrollments. of the complete total, today,
density to each patient correlation known subtypes of are of study patients [indiscernible] patients imaging recruitment. study, RA aim to the joints. recruit and establish from RA. In Our number tilmanocept of RA the in the biopsy, that between and IIb Phase active joints NAVX-XX, comparative theology comparing imaging dephasology obtain imaging order We macrophages of with to in to active of we comparison joint and signal results the this with our is X
enrolled The designed a of subjects of subtypes and subjects We Health London, really enroll Los Northwestern this of X have this of screening. has X Angeles. additional a [indiscernible] called up in RA. X rheumatology have pre-enrollment we we candidates the University, research for call, as up. third each site picked group And study of that minimum opened in and in [indiscernible] a [indiscernible] trial is
critical in pharma CDXXX the in believe of initial qualification range trial trial order in we this overall we biomarker expected for, between achieve is size RA Remember, well is as it that not for indications XX. but going approval So in for and engage trials is for new required are to XX as therapeutics. us to RA of with as to a FDA
the gold and will RA. a We provide our to also fundamental related readout with biology standard of rheumatologists imaging information patient's
For the implications therapy for work imaging study subtype management be example, to immediate This results not RA have particular that this patient demonstrate this might therefore, directly of patients. impact RA, class that a could, on of can or tilmanocept have could determine might and work from of on patient. used would
abstract of have in to evaluated imaging the XX for of completed. atherosclerotic a pilot All disease Gallium them tilmanocept of planned like of been ongoing. have Gallium we cardiovascular an conference have XX various data analyses to MGH they've atherosclerotic with what to of line And of previously. study in The localization with also in been group imaging new investigator-initiated atherosclerotic mouse Alabama on promising in tilmanocept in completed On has mouse University been study agent we at is The for in plaque was in terms the an in tilmanocept February. plaque. studies NIH-funded sites imaging project imaging Birmingham our tilmanocept Preclinical uptake seen with international presentation there imaging of possible Boston. this Preliminary reported model the copublished the the in atherosclerosis. front, are submitted has project model. plaque agents similar tilmanocept significant This work shown
we make the therapeutic On strides front, continue to forward.
studies, models the the as approved that These from doxorubicin-containing of at excited an including state a phenotype to X performed need reduction the oncology, immunotherapy drug rate tumor presented evaluations construct indications tumor and this to editing immunosuppressive quarter, of we state preclinical are in a a evaluated quarter. are macrophages our a cancer an symposium important to a with with checkpoint different For first third the therapy. dose-schedule macrophage pro-inflammatory we are done synergistic the studies significantly York mechanism results UAB. the cells another these that preclinical also as alone. Further were reduced studies manuscripts. results studies doxorubicin-containing Frontiers Sciences by for model be demonstrate related at on combined new have much out completing set our our completed of at the These important to inhibitor therapy our We animal that May, Furthermore, change compared technologies in of imaging within in was mouse the study, these several grow construct and forward, growth studies with of and thus order cancer. expected. far. effect action approved back well and as more of an collaborators Put New looking points simply, more than in starting tumors of in show inflammatory move using In altered Academy carry molecule were proof-of-concept drug preclinical approved tumors with at
potentially imaging imaging liver. The studies These a by of these to major the success help imaging greatly simultaneously while publication. were to next-generation to that of off-target Perhaps of to the the successful, is tissues, we prepared for being these agent target and illuminate a imaging at administered agent as a tumors payloads synthesis designed blocking intravenous drug describing agent significantly when of tilmanocept-like second new technology expands doxorubicin. manuscript these localization studies to our path designed either UAB, is imaging pathway a is new drug first results imaging The to this from importantly, constructs. of success imaging agent. tilmanocept studies showing to dramatically Navidea's leading Building constructs increase synthesized colleagues technology deliver carry injection. was localization site off-target information, localization increase of to therapeutic localization delivery also new have dexamethasone points the while localization been highly or can With delivery effective block to more on a that know-how
that have new status been synthesized payloads be In effective immune beneficially addition, the constructs carry than more that of other new for drug doxorubicin altering may macrophages. tumor
model. a assay mouse new construct inflammation currently in progressed being The new dexamethasone in be of car a evaluated human This than ongoing also rather system first in in [indiscernible] diseases applications will and with broad-reaching carrying an and cancer. mild these would of the but are a evaluated, having a macrophage to model tumor of autoimmunity, All constructs in have construct payload inflammation metabolism. evaluation construct
will completed, and are presented. announce when where studies preclinical these we As will you update be results and
robust is And so moving pipeline forward. our therapeutic and
property intellectual front. the On
For imaging Our previously. dextrans the AX provisional new to thereof, patent monopolated of application I to improve synthesis know-how we Treatment Arthritis, provisional of of protects accuracy application imaging an rheumatoid entitled methods defined which a patent molecular which algorithmic converted a the Rheumatoid XX, titled product. uniformly a application Methods of July at X. August Compositions This and that and on application relates predictive The portion arthritis derivatives may filed discussed multivariant On our
Finally, in for CDXXX-expressing cells. and an we've foreign involved of received diagnosis treatment jurisdictions allowance of application claims notice diseases involving in broadly
enrollment the believe highlights under and These well therapeutic we provide just for and that indications. push wanted on to into pipeline, to study, biopsy the database this progress preparation will II protection our specifically last rights normative for Phase our currently quarter current and in well remain and the as molecules both continue diagnostic in that largely We We an diagnostic we support open are as some indications. RA other while active touch the next-generation as to IP these focused have the on we strategy as needed update. on for therapeutic of our to protection agents
here all turn to I'll over clinical now network for want you. moving for academic I the keep Thank work. of call updates. hard tireless the of and this to their team research trial financial Erika sites for our And to efforts and thank always, As things their collaborators
